MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Tag: NG101

NG101

Latest news

Tag

Gastroenterology

Metopimazine Mesylate (NG101) for Gastroparesis: Evaluating the Gap Between Patient Global Impression and Symptom Severity Scores

A Phase 2 trial of NG101 for gastroparesis missed its primary endpoint for nausea severity on the DIGS-DD scale but demonstrated significant improvements in Patient Global Impression of Change (PGIC) and a favorable safety profile, particul

Feb 4, 2026
Gastroenterology

Metopimazine Mesylate (NG101) in Gastroparesis: Navigating the Complexities of Nausea Management and Trial Endpoints

This Phase 2 trial of NG101 for gastroparesis did not meet its primary endpoint for nausea severity reduction but showed significant global improvement in patient-reported outcomes and a favorable safety profile, particularly in idiopathic

Feb 3, 2026
Gastroenterology

A Glimmer of Hope for the ‘Slow Stomach’: Exploring the New Frontier in Gastroparesis Treatment

This article examines the Phase 2 trial of NG101 (metopimazine), a novel treatment for gastroparesis. While the primary endpoint was missed, significant improvements in patient-reported outcomes and a strong safety profile suggest a potenti

Feb 3, 2026

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story